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Abstract 
Purpose: To establish if there are different classes of inflammatory lacrimal punctum diseases (ILPDs) 
and to examine the various strategies by which they can be managed therapeutically.  
Methods: Two hundred and fifty nine (259) patients with inflammatory punctum lacrimal disease were 
identified and used as subjects for this study.  Each patient was carefully examined for evidence of 
morphology of lacrimal punctum which was confirmed mainly by lacrimal duct flushing and probing. 
Appropriate therapeutic managements were adopted for patients with other inflammatory conditions 
besides ILPD. The clinical effects of the various therapeutic strategies were documented.  .  
Results: Eighty-seven (87) patients out of the 259 (32.53 %) suffered from acute or chronic 
conjunctivitis while 66 patients (5.61 %) suffered from inflammatory lacrimal passage diseases. Patients 
with both conjunctivitis and lacrimal passage inflammation, patients with dry-eye symptoms, patients 
with just one of the conditions, and patients with mere evidence of superior punctalacrimalis 
represented 13.15, 14.19, 14.53, and 33.91 %, respectively.  Mere evidence of inferior punctalacrimalis, 
and presence of acute inflammation were seen in 48.76 and 13.49 % of the 259 patients, respectively, 
while those with chronic inflammation lasting for 2.97 ± 0.13 years, comprised 86.51 %. Antibiotic eye 
drops were used for acute inflammation, while chronic inflammation was treated with antibiotic eye 
drops, lacrimal punctum expansion, pus elimination, and punctum-sparing canaliculotomy. Both 
therapeutic methods produced satisfactory curative effects.  
Conclusion: The results show that satisfactory therapy of lacrimal punctum inflammation can be 
achieved if the right therapeutic agents and procedures are adopted based on clinical characteristics of 
the ILPD manifesting in the patient.  
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The lacrimal punctum is located at the bi- 
temporal of the inner canthus, at the junction of 
the ciliary and lacrimal parts of the superior and 
inferior palpebral margin, which is the initiating 
terminal of the lacrimal passage. Inflammatory 
disease obstructs the flow of tears into the 
lacrimal passage resulting in epiphora [1-4].  
Presently, there is paucity of information in the 
literature on the clinical characteristics and 
pathological course of inflammatory lacrimal 
punctum disease. Previously, it was believed that 
inflammatory lacrimal punctum disease occurred 
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along with conjunctivitis and canaliculitis, and 
that the severity is predicated on concomitant 
development of conjunctivitis and canaliculitis. 
 
However, no specific study on lacrimal punctum 
appears to have been carried out with published 
results. Based on clinical observation, it is 
possible to know that inflammatory lacrimal 
punctum disease has specific features, and that 
in the course of the disease, it may or may not be 
associated with conjunctivitis or inflammation of 
other lacrimal passages. It is anticipated that the 
results obtained from the clinical observations in 
this study will form the basis for providing a 
general description of its occurrence, 
development, and treatment outcomes, thereby 
adding new information to our current knowledge 
of this disease. Furthermore the findings may 
provide information on therapeutic methods that 
may be explored in the management of different 




Data from 259 patients with puncta lacrimalis 
(289 eyes) treated in the Department of Lacrimal 
Apparatus Disease of Shenzhen Eye Hospital 
from January 2008 to December 2013 were 
analyzed retrospectively. The 259 patients 
consisted of 131 males (with 165 infected eyes) 
and 128 females (with 142 infected eyes), with 
ages ranging from 13 to 82 (mean age = 51.8 ± 
5.31 years). In some patients, symptoms of the 
disease were noticed 2 weeks before reporting at 
the hospital whereas in others the time interval 
between the appearance of symptoms and 
hospital visitation ranged between three weeks to 
20 years. The average time lapse from onset of 
symptoms to hospital visitation was 2.8 ± 1.22 
years. Patients with congenital lacrimal passage 
abnormalities and patients who suffered from 
abnormal lacrimal punctum structures and 
functions due to certain trauma were excluded 
from this study. This study was approved by the 
ethics committee of the Affiliated Shenzhen Eye 
Hospital of Jinan University, Shenzhen, China 
(approval no. [2014]-JNU-005) and was carried 
out in accordance with the Guidelines of the 





Each patient’s medical history was carefully 
documented. With the aid of slit lamp, the shape 
of the lacrimal punctum, position, and condition 
of the lacrimal caruncle, halfmoon wrinkle wall, 
palpebral conjunctiva, and bulbar conjunctiva 
were examined. Lacrimal duct flushing and 
probing, and other examinations were performed. 
Pictures were taken with the slit-lamp 
microscope, and the characteristic changes 
observed during the course of the disease were 
recorded. Furthermore, appropriate therapeutic 
modalities were adopted for the management of 





Data analyses were performed using the SPSS 
20.0 statistical software package. The data are 
presented as mean ± standard deviation (SD). 
Student’s t test was used to evaluate significant 
differences between groups. P < 0.05 was 




Among the 259 patients (289 infected eyes) who 
suffered from inflammatory lacrimal punctum 
disease were 87 patients (94 infected eyes) 
comprising 32.53 % of the infected eyes, with 
acute or chronic conjunctivitis. Sixty-nine patients 
(with 74 infected eyes) had other diseases of the 
lacrimal passage, such as canaliculitis and 
dacryocystitis. They constituted 25.61 % of the 
total number of infected eyes. Thirty-four patients 
(38 infected eyes) suffered from both 
conjunctivitis and lacrimal passage inflammation, 
and constituted 13.15 % of the total number of 
the infected eyes of patients included in the 
study. Thirty-two patients (with 41 infected eyes) 
suffered from dry-eyes and they formed 14.19 % 
of the total number of infected eyes, while 37 
patients (42 infected eyes) suffered from lacrimal 
punctum inflammation and constituted 14.53 % 
of the total number of infected eyes. 
 
Among all the patients who suffered from 
inflammatory lacrimal punctum disease, 93 
(having 98 infected eyes) had superior puncta 
lacrimalis, which was 33.91 % of the infected 
eyes, while 129 patients (141 infected eyes) had 
inferior puncta lacrimalis, and constituted 48.79 
% of the infected eyes. Thirty-seven patients (50 
infected eyes) suffered from both inferior and 
superior puncta lacrimalis, which translated to 
17.30 % of the infected eyes. 
 
The patients who suffered from inflammatory 
lacrimal punctum disease were divided into acute 
inflammation and chronic inflammation groups 
according to the duration of the disease. There 
were 37 patients (with 39 infected eyes), and 
13.49 % of the total number of infected eyes had 
acute inflammation. The clinical manifestations 
included sudden and acute attacks, and the 
course of the disease was generally 4 weeks. All 
the patients also had redness of the eye, swelling 
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and pain due to the diseased palpebral bulbar 
conjunctiva of the inner canthus, which in some 
cases involved the eyelid and skin of the inner 
canthus. The patients often experienced itching 
and flow of tears, and other symptoms in the 
inner canthus.  
Physical signs of the disease were observed at 
the center of the lacrimal punctum aperture, the 
lacrimal punctum wall, and the surrounding 
palpebral conjunctiva centripetally, resulting in 
hyperemia and edema. In the marginal zones of 
the redness and swelling, the palpebral 
vasculature of the conjunctiva presented with 
plentiful and circuitous angiectasis (Figure 1A). 
Due to redness and swelling, the lacrimal 
punctum aperture showed a closed morphology, 
Generally, the surfaces of the affected eyes were 
coated with inflammation exudates. Seven 
patients (with 7 infected eyes) had acute 
canaliculitis, which presented as typical emulsion 
drop (Figure 1B). For these patients, antibiotic 
eye drops and symptomatic treatment were used 
to manage the associated conjunctivitis, 
canaliculitis [6], dacryocystitis, and dry-eye 
symptoms. After the redness and swelling 
gradually vanished, the lacrimal passage was 
flushed, and the inflammation eventually 
resolved completely. 
 
There were 222 patients (250 infected eyes) with 
chronic inflammation that covered 86.51 % of the 
eyes. For these patients, the onset of the disease 
was slow. The shortest course of the disease 
was 4 weeks, and the longest was 20 years, with 
an average of 2.97 ± 0.13 years. They also 
suffered from chronic conjunctivitis, which at 
times developed from acute inflammation.  
 
The major symptoms were lacrimation and 
itching that was sensed in the inner canthus. 
Some of the patients presented with lacrimation 
when exposed to wind. With exacerbation of 
inflammation, the tears were accompanied by 
mucous secretion. During the initial period of 
inflammation, it presented as an acute attack, but 
if not treated, the illness gradually worsened. 
Type I puncta lacrimalis (lacrimal punctum 
centrality shrink type) was identified in 105 
patients (120 infected eyes), comprising 48 % of 
cases of chronic inflammation. In these patients, 
the palpebral conjunctiva was found to have 
developed from the four sides of the lacrimal 
punctum to the lacrimal punctum as the central 
portion of the lacrimal punctum shrank (Figure 
2A).  
 
Type II (vitreoretinopathy coverage type) was 
identified in 42 cases (47 infected eyes), which 
constituted 18.8 % of those in the chronic 
inflammation group. Type II was evidenced by 
reduction and flatness of some parts of the 
papilla cyclic annular dam apophysis, ligule 
shape vitreoretinopathy of the palpebral 
conjunctiva access and covering of lacrimal 
punctum aperture from the flat position (Figure 
2B). Type III was also identified (lacrimal 
punctum aperture close type) in 39 cases (44 
infected eyes), which translated to 17.60 % of all 
chronic inflammation cases. It presented as lack 
of hyperemia and edema, but the palpebral 
conjunctiva around the lacrimal punctum showed 
angiectasis along with neovascularization. The 
palpebral conjunctiva around the lacrimal 
punctum aperture presented with proliferation 
and hypertrophy, embedding the lacrimal 
punctum wall and obstructing the lacrimal 
punctum aperture.  
 
However, when the fleshy and proliferative 
conjunctiva were removed, the lacrimal punctum 
aperture could be seen (Figure 2C).Type IV 
(lacrimal punctum pus embedding type) was 
 
Figure 1: Acute lacrimal punctum inflammation (A = Redness and swelling due to the palpebral bulbar 
conjunctiva of inner canthus; B = Emulsion droplet shape) 
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identified in 25 cases (27 infected eyes), which 
constituted 10.80 % of chronic inflammation 
cases. It presented as   proliferating palpebral 
conjunctiva wrapping around the thick pus and 
lacrimal punctum aperture, forming  a white 
molehill-like protrusion on the lower eyelid  
(Figure 2D).Type V (lacrimal punctum vanished 
type) was also identified in  11 cases (12 infected 
eyes), comprising 4.8 % of the chronic 
inflammation cases. It presented as atrophy of 
the lacrimal punctum wall and surrounding 
tissues. The cyclic annular dam tissue was flat, 
and the lacrimal punctum aperture could not be 
entirely seen (Figure 2E). 
 
For each of the above 5 groups of patients, 
different methods of therapy were applied. In 
type I group of patients, antibiotic eye drops were 
used and lacrimal passage expansion was 
performed with lacrimal puncta expander. For the 
type II group, antibiotic eye drops were used, and 
after one week of usage shrinkage of parts of the 
patients’ vitreoretinopathy occurred. In cases 
where vitreoretinopathy still covered the lacrimal 
punctum aperture, resection of the parts of the 
vitreoretinopathy that covered the lacrimal 
punctum was done, followed by “lacrimal 
punctum expansion”. For the type III group, 
antibiotic eye drops were used first, and 
thereafter lacrimal punctum angioplasty was 
performed. For the type IV group, resection of 
the encapsulated mucosal tissue was done to 
release the tenuous fester, and this was followed 
by angioplasty of the lacrimal punctum. After the 
therapies, patients’ puncta lacrimalis were no 
longer evident and the lacrimal punctum 




The lacrimal punctum is the entrance of the tear 
excretory system to the eye. Under normal 
circumstances, the superior lacrimal punctum is 
located 6.0 mm inferior and posterior from the bi-
temporal site of the inner canthus. The inferior 
lacrimal punctum is located 6.5 mm superior and 
posterior from the bi-temporal site of the inner 
canthus. The normal lacrimal punctum diameter 
is 0.2 to 0.3 mm, but it expands slightly with age. 
The lacrimal punctum is the open-end of the 
lacrimal canaliculus similar to the mouth of a 
well, which is open and bare on the surface of 
palpebral conjunctiva. It consists of the lacrimal 
punctum mouth, the lacrimal punctum wall and 
the lacrimal punctumpapilla (Figure 3). 
 
On the surface of the periphery of the lacrimal 
punctum wall, the palpebral conjunctiva is thick, 
presenting as a dam apophysis, which is called 
the lacrimal punctum papilla. Within its deep 
layer is the lacrimal canaliculus, which is 
surrounded by the lacrimal punctum sphincter.
 
Figure 2: Chronic lacrimal punctum inflammation (A = Type 1 Lacrimal punctum type with shrinkage of the 
central portion; B = Type 2 Lacrimal punctum vitreoretinopathy coverage type; C = Type 3 Lacrimal punctum 
mouth close type; D = Type 4 Lacrimal punctum pus embedding type E = Type 5 Lacrimal punctum vanishing 
type) 
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Figure 3: Lacrimal punctum (1 =. Lacrimal punctum 
mouth; 2 =. Lacrimal punctum wall; 3 =.Lacrimal 
punctum papilla) 
 
Under normal circumstances, the lacrimal 
punctum aperture fits closely on the surface of 
the eyeball. It is located at the bottom of the tear 
lake. When the eyelid closes and opens, the 
superior lacrimal punctum slides into the shallow 
trench between the conjunctiva half-moon 
wrinkle wall and lacrimal caruncle, and the 
inferior lacrimal punctum slides into the shallow 
trench between the half-moon wrinkle wall and 
the eyeball.  
 
The physiological functions of the lacrimal 
punctum includes absorbing tears into the 
lacrimal canaliculus and maintaining and 
stabilizing the normal cycle of tears on the 
surface of the eyeball through the movement of 
the lacrimal punctum sphincter. Due to the 
anatomical position of the lacrimal punctum, it is 
easily infected. Thus conjunctivitis and 
canaliculitis may spread to the lacrimal punctum 
[1]. Inflammatory lacrimal punctum disease and 
its clinical characteristics and disease the right 
therapeutic methods were examined in this 
study. In 259 cases (289 eyes) of lacrimal 
punctum inflammatory disease, patients who 
suffered from acute or chronic conjunctivitis 
comprised 32.53 % of the cases, those who 
suffered from other inflammatory processes of 
the lacrimal passage comprised 25.61 %, and 
those with both conjunctivitis and lacrimal 
passage inflammation comprised 13.15 %. The 
data in our study is consistent with the previous 
published study [8]. The reason for this is that the 
conjunctiva, lacrimal punctum, lacrimal 
canaliculus, and lacrimal sac are connected to 
each other.  
 
The inflammation of the conjunctiva, lacrimal 
canaliculus, and lacrimal sac may affect the 
lacrimal punctum, and their disease courses are 
more or less the same. This is probably why 
inflammatory lacrimal punctum disease has not 
received enough attention in clinical practice. 
Some patients with dry eyes were identified in 
this study. These patients generally will have 
recurrence within 1 - 2 years of the first dry-eye 
symptoms [9-11]. During the initial stages, their 
symptoms were off and on but when the course 
of the disease become protracted, the lacrimal 
punctum may be blocked. These patients 
generally need to be treated with lacrimal 
implants, which undoubtedly will enhance 
lacrimal punctum function. 
 
However lacrimal punctum implants that should 
be used are the ones that will not irritate the 
lacrimal punctum when treating dry-eyes. In 
addition, during therapy efforts should be made 
to ascertain whether a patient is wearing an 
implant or not. Patients suffering from 
inflammatory lacrimal punctum disease, but who 
had puncta lacrimalis alone were among the 
patients included in this study. In these patients it 
is likely that the conjunctiva and lacrimal 
canaliculus are affected. However, clinicians 
usually neglect the diagnosis and therapy of 
idiopathic puncta lacrimal inflammation and focus 
on the treatment for conjunctivitis and 
canaliculitis only.  
 
Of all the patients suffering from inflammatory 
lacrimal punctum disease, patients who merely 
presented with superior puncta lacrimalis were 
33.91 %, and those who presented with inferior 
lacrimal punctum were 48.79 %. The present 
study provided the similar findings compared to 
the previous published studies [12,13]. The high 
percentage of the latter may be due to the low 
position of inferior lacrimal punctum, where tears 
and other pathogenic factors collecting.  
 
It is likely that the disease worsens from Type I to 
Type V. At the onset of the disease, the mouth of 
the lacrimal punctum presents with central 
shrinkage due to the swelling. If untreated, the 
palpebral conjunctiva swelling will aggravate and 
gradually cover the mouth of the lacrimal 
punctum, which presents as vitreoretinopathy 
coverage type. The vitreoretinopathy will 
eventually cover the lacrimal punctum entirely, 
but after treatment, the lacrimal punctum mouth 
can be seen. Then, with worsening of the 
disease, pus is wrapped in the lacrimal punctum 
mouth, resulting in the pus embedding type. 
Finally, complete resolution of the lacrimal 
punctum represents the lacrimal punctum 
vanished type.  
 
Ye et al 
Trop J Pharm Res, August 2017; 16(8): 2024  
 
Based on the different disease courses, selected 
antibiotic eye drops, lacrimal punctum expansion, 
clearing of pus, lacrimal punctum shaping, and 
other treatments that were adopted produced 
satisfactory cures.  
 
Limitations of the study 
 
Although this study revealed some interesting 
results, there are also a few limitations. First, 
although 259 patients with inflammatory puncta 
lacrimalis disease were involved in this study, the 
sample size is considered small. Second, the 
outcomes could not be fully analyzed. Third, it 
was difficult to access the right drugs normally 
used for the therapeutic management of 




Lacrimal punctum inflammation is a disease of 
distinct clinical manifestations with clearly 
defined course of development. The findings of 
the study indicate that satisfactory therapy of the 
inflammation can be achieved if the right 
therapeutic agents and procedures are adopted 
based on the clinical characteristics of the ILPD 
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